Part two. The comments wrote this one. The post on the absent randomized trial data behind BPC-157, TB-500, and MOTS-c got the response you would expect from a cash-pay industry whose products lack the studies to support them: ferocious volume. Hundreds of comments, almost none citing a published trial, most of them following the same three rhetorical patterns that surface under every peptide thread on the internet. That pattern is itself a finding. The personal attack. "Dogmatic. Academic neanderthal. Intellectually deficient. Get your head out of your book." When the molecule cannot defend itself, the messenger gets the treatment. The deflection. "Stay in your lane. It is a personal choice. Why do you even care? MILLIONS are taking it, the anecdotes speak for themselves..." Asking a muscle, tendon, and metabolism researcher to stop talking about muscle, tendon, and metabolism interventions is not a coincidence. It is a request to vacate the lane the marketing has parked in. And m...